SCHEMBL10003285

SCHEMBL10003285

CCOC(=O)c1c(OCC)c2nc(NC(=O)c3ccccc3)c(CC)cc2n1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.49
▸ DHODH Q02127 1/20 0.45
▸ ADORA2A P29274 1/20 0.45
▸ ADORA1 P30542 1/20 0.45
▸ SMN1; SMN2 Q16637 7/20 0.44
▸ NPC1 O15118 7/20 0.44
▸ RAB9A P51151 6/20 0.44
▸ GAA P10253 1/20 0.44
▸ ALDH1A1 P00352 7/20 0.44
▸ HPGD P15428 2/20 0.44
▸ MAPT P10636 4/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ ABCB1 P08183 1/20 0.42
▸ ABCG2 Q9UNQ0 1/20 0.42
▸ LMNA P02545 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10002854 0.92 P2RX3 (0.41) HTTDHODHADORA1SMN1; SMN2NPC1
SCHEMBL10003128 0.91 HTT (0.44) HTTDHODHADORA2AADORA1SMN1; SMN2
SCHEMBL10003720 0.83 SMO (0.39) HTTADORA1NPC1RAB9AALDH1A1
SCHEMBL10003836 0.81 ADORA2A (0.44) ADORA2AADORA1SMN1; SMN2NPC1RAB9A
SCHEMBL10003186 0.81 BRPF1 (0.44) HTTADORA2AADORA1SMN1; SMN2NPC1
SCHEMBL10002969 0.80 KMT2A (0.44) SMN1; SMN2NPC1RAB9AGAAALDH1A1
SCHEMBL10003352 0.79 MAPT (0.40) SMN1; SMN2NPC1RAB9AGAAALDH1A1
SCHEMBL10003263 0.77 HSD17B10 (0.52) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL10004349 0.75 HTT (0.44) HTTDHODHADORA2AADORA1SMN1; SMN2
SCHEMBL10003086 0.74 HTT (0.45) HTTDHODHADORA2AADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH HTT 3635/4885DHODH 48/4885ADORA2A 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback